Shares of Hims & Hers Health Inc. (HIMS) tumbled 12.39% in a 24-hour period following the release of its second quarter 2025 financial results. The telehealth company's stock decline came despite beating earnings estimates, as revenue fell short of expectations.
Hims & Hers reported Q2 revenue of $544.8 million, marking a substantial 73% increase year-over-year. However, this figure missed the analyst estimates of $551.6 million. On a positive note, the company's earnings per share (EPS) of $0.17 surpassed the expected $0.15. The number of subscribers grew by 31% to over 2.4 million compared to the previous year.
The revenue miss was primarily attributed to a decline in the company's GLP-1 weight-loss drug business, which generated $190 million in online revenue during the second quarter, down from $230 million in the first quarter. Additionally, the company's sexual health business experienced a slowdown. Despite these challenges, Hims & Hers maintained its full-year 2025 guidance, projecting revenue between $2.3 billion and $2.4 billion. The company emphasized its commitment to providing personalized, high-quality care and entering new, high-impact specialties, but investors seemed concerned about the short-term revenue challenges and potential regulatory hurdles in the weight-loss drug market.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。